H2L carcinomas significantly differed from HER2-positive carcinomas regarding the activation of the MAPK pathway (p = 0.0073; Figure 3C), with a stronger pathway activation correlating with the activation of various genes in this pathway. This evidence concerns the gene ERBB2 and carcinoma.